Interview

Tc99m tilmanocept only US FDA approved drug for lymph node biopsy in clinically node negative breast cancer patients :Vandana Subramania, Sayre Therapeutics

Sayre Therapeutics specializes in innovative treatments and medical devices commercialization in South Asia. Vandana Subramanian, Chief Business Officer & Co-founder, Sayre Therapeutics Pvt. Ltd says Sayre

accelerates product access to patients in South Asia by partnering with global companies having limited or no commercial footprint in South Asia.

Kindly comment on the rising cost of treatment of cancer in India.

Cancer treatment has become a big challenge as the baseline treatment cost is Rs 3-5 lakh and can go up to Rs 10-15 lakh, affordability is a significant challenge for cancer treatment.

Majority of patients are not able to afford targeted drugs in cancer treatment that are required in advanced stages which can average a baseline treatment of ~4 lakhs to more targeted chemotherapy options of 15 lakhs. The government continues to make strides in building insurance schemes for the lower socio-economic demography, however it covers only a minuscule portion of the patient’s expenses and can certainly not cover targeted cancer care.

I understand that Sayre Therapeutics works in the field of oncology and immunology tell us about your products?

According to ICMR(Indian Council for Medical Research),India is likely to have over 17.3 lakh new cases of cancer and over …

To read more subscribe
Tags
Show More

Related Articles

Leave a Reply

Close